MS&E 228: Applied Causal Inference Powered by ML and AI

Lecture 6: Variance of the DR Estimator and Variance Reduction in Experiments

Vasilis Syrgkanis

Stanford University

Winter 2026

Readings: *Applied Causal Inference Powered by ML and AI*, §9-10.

Goals for Today

1. Understand the pros and cons of all estimators we've learned thus far.
2. See examples of how these estimators are being applied in practice.
3. Understand why the **doubly robust (DR) estimator** is not just robust, but also **statistically efficient**.
4. Decompose the **variance of the DR estimator** to see what drives its precision.
5. Learn how **regression adjustment** can be used to **reduce variance** in Randomized Controlled Trials (RCTs).

Part I: Recap and In-Class Activity

Consolidating our ATE Estimation Toolbox

Recap: The ATE Estimation Landscape

We have built up a rich toolbox of estimators for ATE under conditional exogeneity and overlap:

- Linear regression adjustment (g-formula with linear model)
- G-estimator with generic ML for outcome regression (T-learner and S-learner)
- IPW estimator with generic ML for propensity
- IPW with un-penalized logistic regression for propensity
- DR estimator with ML for outcome and propensity (T- and S-learner variants)
- DR estimator with semi-cross-fitting
- DR estimator with stacked semi-cross-fitting

In-Class Activity (15 min)

Group Discussion: Algorithm Comparison

In your groups, discuss the estimators from the previous slide. Fill out a table with the following columns:

- Estimator
- Pros
- Cons
- When to Use

Be ready to share one key insight.

Poll 1

Poll Question

Which estimator would you choose for a setting where you believe the propensity is easy to learn but the outcome regression model might be hard to learn?

A. IPW with ML
B. G-formula with ML
C. Doubly Robust estimator
D. Linear regression adjustment

(Poll Everywhere)

Part II: Case Study

Aspirin, Pregnancy, and Per-Protocol Effects

In-Class Activity: Reading the Paper (10 min)

Reading Zhong et al. (2022) JAMA Network Open

Discuss in your groups:

1. What is the treatment?
2. What is the outcome?
3. What are the key confounders?
4. Why is this not a simple RCT analysis?
5. What specific DR configuration was used?

Figure: Paper Click Here

Figure: Supplementary Material 2: Click Here

The EAGeR Trial: Aspirin and Pregnancy

Study: Effects of Aspirin in Gestation and Reproduction (EAGeR) trial.

- **Design:** Multicenter, block-randomized, double-blind, placebo-controlled clinical trial.
- **Participants:** 1,227 women with a history of pregnancy loss.
- **Intervention:** Daily low-dose aspirin (81 mg) vs. placebo.
- **Outcome:** hCG-detected pregnancy.
- **Follow-up:** Up to 6 menstrual cycles for attempted pregnancy.

Why Per-Protocol Analysis?

- **Intention-to-Treat (ITT):** Effect of *assignment* to treatment.
  - Preserves randomization.
  - Can be diluted by non-adherence.
- **Per-Protocol Effect:** Effect of *adhering* to the treatment protocol.
  - Often the scientific question of interest.
  - Breaks randomization—adherence is a choice!
- **The Challenge:** Per-protocol analysis of an RCT must be treated as an **observational study**, because adherence can be confounded by baseline and post-randomization factors.

EAGeR Trial: Key Results

Analysis	**Effect Estimate**	**95% CI**
Intention-to-Treat (ITT)	$+4.3$ per 100 women	$(-1.1, 9.6)$
Per-Protocol (DR with ML)	$+8.0$ per 100 women	$(2.5, 13.6)$

Key Insight: The per-protocol effect is nearly twice as large and statistically significant. Adherence matters, and flexible ML-based DR methods can uncover effects that ITT misses.

In-Class Activity: Reading the Paper (10 min)

Reading Zhong et al. (2022) JAMA Network Open

Discuss in your groups:

1. What is the treatment? (Adherence: ≥ 5 of 7 days/week for $\geq 80\%$ of follow-up)
2. What is the outcome? (hCG-detected pregnancy)
3. What are the key confounders? (Baseline: age, BMI, prior losses; Post-randomization: bleeding, nausea)
4. Why is this not a simple RCT analysis?
5. What specific DR configuration was used? (AIPW with Super Learner: GLM, MARS, RF, XGBoost)

Part III: DR in Practice

Industry Packages and Applications

EconML: LinearDRLearner (Microsoft)

```python
from econml.dr import LinearDRLearner
from sklearn.ensemble import RandomForestRegressor, RandomForestClassifier

# S-learner variant by default
est = LinearDRLearner(
    model_propensity=RandomForestClassifier(),
    model_regression=RandomForestRegressor()
)
est.fit(Y, T, X=None, W=X)

# Get ATE and confidence intervals; the `intercept_` parameter
est.summary()
```

Note: Uses S-learner API by default. T-learner can be emulated by passing a model that trains separate models for treated/control.

DoubleML: IRM (DoubleML Package)

```python
from doubleml import DoubleMLIRM, DoubleMLData
from sklearn.ensemble import RandomForestRegressor, RandomForestClassifier

# Prepare data
dml_data = DoubleMLData(df, y_col='Y', d_cols='D', x_cols=X_cols)

# T-learner API: separate models for E[Y|X,D=d]
ml_g = RandomForestRegressor()
ml_m = RandomForestClassifier()

dml_irm = DoubleMLIRM(dml_data, ml_g, ml_m, score='ATE')
dml_irm.fit()

print(dml_irm.summary)
ci = dml_irm.confint(level=0.95)
```

Note: Uses T-learner API—the model passed will be used to train separate models for treated and control.

Industry Application: Uber

Blog Post: "Using Causal Inference to Improve the Uber User Experience"
`https://www.uber.com/blog/causal-inference-at-uber/`

- Uber uses DR ML-based estimators for measuring treatment effects in observational studies.
- Real-world scale: millions of users, complex treatment assignment mechanisms.
- Key considerations: computational efficiency, robustness to model misspecification.

Takeaway: These methods are not just academic—they are deployed in production at major tech companies and are used by empirical researchers in a variety of fields.

Part IV: Variance of the DR Estimator

Understanding Efficiency

The Semiparametric Efficiency Bound

Key Theorem

In observational settings and in RCTs, the DR estimator achieves the **semiparametric efficiency bound**. This means no other asymptotically unbiased estimator can have a smaller asymptotic variance without making additional assumptions (e.g., linearity of the outcome regression).

Why this matters:

- DR is not just robust (double robustness), it's also **optimally precise**.
- If you're willing to make stronger assumptions (e.g., linear CEF), you can do better (e.g., OLS has lower variance under linearity).

Unpacking the Variance Formula (1/5)

Let $\psi_0(Z)$ be the DR score (influence function) at the true nuisance functions g_0, p_0:

$$\psi_0(Z) = \underbrace{g_0(1,X) - g_0(0,X)}_{\text{G-formula part}} + \underbrace{a_0(D,X) \cdot (Y - g_0(D,X))}_{\text{IPW correction part}}$$

where $a_0(D,X) = \frac{D}{p_0(X)} - \frac{1-D}{1-p_0(X)} = \frac{D-p_0(X)}{p_0(X)(1-p_0(X))}$.

We want to compute $\mathrm{Var}(\psi_0(Z)) = \mathbb{E}[(\psi_0 - \mathrm{ATE})^2]$.

Unpacking the Variance Formula (2/5)

Expanding the variance:

$$\begin{aligned}\mathrm{Var}(\psi_0) = &\underbrace{\mathbb{E}[(g_0(1,X) - g_0(0,X) - \mathrm{ATE})^2]}_{\text{Term A: Variance of CATE}} \\ &+ \underbrace{\mathbb{E}[a_0(D,X)^2 (Y - g_0(D,X))^2]}_{\text{Term B: Weighted Noise}} \\ &+ \underbrace{2\mathbb{E}[(g_0(1,X) - g_0(0,X) - \mathrm{ATE}) \cdot a_0(D,X)(Y - g_0(D,X))]}_{\text{Term C: Cross-term}}\end{aligned}$$

Unpacking the Variance Formula (3/5)

The cross-term C vanishes!

By the law of iterated expectations:

$$\begin{aligned} C &= 2\mathbb{E}\Big[(g_0(1,X) - g_0(0,X) - \mathrm{ATE}) \cdot a_0(D,X) \cdot \mathbb{E}[Y - g_0(D,X) \mid D, X]\Big] \\ &= 2\mathbb{E}\Big[(g_0(1,X) - g_0(0,X) - \mathrm{ATE}) \cdot a_0(D,X) \cdot 0\Big] \\ &= 0 \end{aligned}$$

This is because $\mathbb{E}[Y \mid D, X] = g_0(D, X)$ by definition of the true conditional expectation function.

Unpacking the Variance Formula (4/5)

Simplifying Term A:

$$A = \mathbb{E}[(\mathrm{CATE}(X) - \mathrm{ATE})^2] = \mathrm{Var}(\mathrm{CATE}(X))$$

where $\mathrm{CATE}(X) = g_0(1, X) - g_0(0, X)$ is the Conditional Average Treatment Effect.

Simplifying Term B:
Let $\epsilon = Y - g_0(D, X)$ be the residual noise. Define $\sigma^2(d, X) = \mathrm{Var}(Y \mid D = d, X)$ (heteroskedastic noise).

$$B = \mathbb{E}[a_0(D, X)^2 \cdot \mathbb{E}[\epsilon^2 \mid D, X]] = \mathbb{E}[a_0(D, X)^2 \cdot \sigma^2(D, X)]$$

Unpacking the Variance Formula (5/5)

Expanding $a_0(D,X)^2$ and using $\mathbb{E}[D \mid X] = p_0(X)$:

$$\begin{aligned} B &= \mathbb{E}\left[\frac{D}{p_0(X)^2}\sigma^2(1,X) + \frac{1-D}{(1-p_0(X))^2}\sigma^2(0,X)\right] \\ &= \mathbb{E}\left[\frac{\sigma^2(1,X)}{p_0(X)} + \frac{\sigma^2(0,X)}{1-p_0(X)}\right] \end{aligned}$$

The Semiparametric Efficiency Bound

$$\mathrm{Var}(\psi_0) = \underbrace{\mathrm{Var}(\mathrm{CATE}(X))}_{\text{CATE Heterogeneity}} + \underbrace{\mathbb{E}\left[\frac{\sigma^2(1,X)}{p_0(X)} + \frac{\sigma^2(0,X)}{1-p_0(X)}\right]}_{\text{Weighted Noise Variance}}$$

Interpreting the Variance Components

Component 1: $\mathrm{Var}(\mathrm{CATE}(X))$

- Captures how much the treatment effect varies across individuals.
- More heterogeneous effects $\Rightarrow$ higher variance.

Component 2: $\mathbb{E}\left[\frac{\sigma^2(1,X)}{p_0(X)} + \frac{\sigma^2(0,X)}{1-p_0(X)}\right]$

- Captures how noisy outcomes are, weighted by inverse propensity.
- When $p_0(X) \approx 0$: we care a lot about $\sigma^2(1, X)$ (few treated).
- When $p_0(X) \approx 1$: we care a lot about $\sigma^2(0, X)$ (few controls).
- **Worst case:** We tend to not treat people with noisy outcomes under treatment, AND we tend to treat people with noisy outcomes under control.

Poll 2

Poll Question

In which scenario would you expect the DR estimator to have the highest variance?

A. High treatment effect heterogeneity, balanced propensity
B. Low treatment effect heterogeneity, extreme propensity
C. High treatment effect heterogeneity, extreme propensity
D. Low treatment effect heterogeneity, balanced propensity

Part V: Variance Reduction in RCTs

Getting More Precise Estimates

The Main Question in RCTs

If we have pre-treatment variables X in an experiment, how can we use them?

Main idea: Use covariates to **reduce variance** by explaining away predictable variation in the outcome.

Example: In a medical trial, patients with prior conditions will have worse survival. Users with high prior engagement will engage more in the future. Why not "center" outcomes around these explainable parts?

Two-Means Estimator Variance

Consider an experiment where we treat with probability q. The simple two-means estimator is:

$$\hat{\theta}_{\text{TM}} = \bar{Y}_1 - \bar{Y}_0$$

Its variance is:

$$\text{Var}(\hat{\theta}_{\text{TM}}) = \frac{\text{Var}(Y \mid D = 1)}{q} + \frac{\text{Var}(Y \mid D = 0)}{1 - q}$$

Problem: We pay for *all* the variance of Y, even the parts that are perfectly predictable from covariates X.

The Ideal: Residual Variance

Ideally, we would want:

$$\frac{\mathrm{Var}(Y - g(1, X) \mid D = 1)}{q} + \frac{\mathrm{Var}(Y - g(0, X) \mid D = 0)}{1 - q}$$

This is the variance of the *residuals* after removing the predictable part.

Recall: The DR variance in an RCT (where $p(X) = q$) simplifies to:

$$\mathrm{Var}(\mathrm{CATE}(X)) + \frac{\mathbb{E}[\sigma^2(1, X)]}{q} + \frac{\mathbb{E}[\sigma^2(0, X)]}{1 - q}$$

Note: $\mathbb{E}[\sigma^2(1, X)] = \mathbb{E}[(Y - g_0(1, X))^2 \mid D = 1]$. So DR achieves roughly this ideal!

DR in RCTs: Key Simplifications (1/2)

In an RCT with treatment probability q:

- The propensity score is **known and constant**: $p(X) = q$.
- The Horvitz-Thompson weights simplify:

$$a(D) = \frac{D}{q} - \frac{1-D}{1-q} = \frac{D-q}{q(1-q)}$$

  Note: This no longer depends on X!

- The DR formula becomes:

$$\hat{\theta}_{\mathrm{DR}} = \mathbb{E}_n[\hat{g}(1,X) - \hat{g}(0,X)] + \mathbb{E}_n\left[\frac{D-q}{q(1-q)}(Y - \hat{g}(D,X))\right]$$

DR in RCTs: Key Simplifications (2/2)

What about our convergence conditions?

- **Product rate condition:** $\sqrt{n} \cdot \mathrm{RMSE}(\hat{g}) \cdot \mathrm{RMSE}(\hat{p}) \to 0$
  - Automatically satisfied since $\mathrm{RMSE}(\hat{p}) = 0$ (we know p exactly).
- **Propensity consistency:** $\hat{p} \to p_0$
  - Trivially satisfied since $\hat{p} = q = p_0$.
- **Outcome regression consistency:** $\hat{g} \to g_0$?
  - **Surprisingly, NOT needed!** We only need $\hat{g} \to g_*$ for *some* limit g_*.

A Surprising Result: No Consistency Needed

Key Insight

In an RCT, we only need $\hat{g}$ to converge to *some* limit g_*, not necessarily the true CEF g_0.

Examples:

- Linear regression over low-dimensional features: converges to the population best linear predictor (minimizing RMSE over all linear functions).
- Lasso over high-dimensional features: under sparsity, also converges to the best linear predictor.

DR is asymptotically normal and centered at the true ATE, with variance:

$$V(g_*) := \mathrm{Var}(g_*(1, X) - g_*(0, X) + a(D)(Y - g_*(D, X)))$$

The Catch!

Key Insight

In an RCT, we only need $\hat{g}$ to converge to *some* limit g_*, not necessarily the true CEF g_0. DR is asymptotically normal and centered at the true ATE:

$$\sqrt{n}(\hat{\theta} - \text{ATE}) \overset{a}{\sim} N(0, V(g_*))$$

Catch!

The limit variance $V(g_*)$ is not the semi-parametric efficient variance $V(g_0)$.

Key Question (Next Lecture)

The limit variance of the DR when the outcome regression converges to a limit $g_* \neq g_0$ can be larger than best variance achievable. Is it even guaranteed that it is better than the variance of the two-means estimate, no matter what g_* is?

Summary: Four Key Takeaways

1. The DR estimator achieves the **semiparametric efficiency bound**—it's optimally precise in observational settings.
2. DR variance depends on **CATE heterogeneity** and **noise amplified by extreme propensities**.
3. In RCTs, regression adjustment can **reduce variance**.
4. In RCTs, DR estimator is consistent and asymptotically normal for the ATE, even if outcome regression does not converge to the CEF but to some other limit g_*.

Next Time

- Examine precision improvement in RCTs via linear adjustment
- Revisiting and gaining a deeper understanding of OLS from a different perspective
- Continuous Treatments. Partially linear models and another "insensitive" formula.

References

- Zhong, Y., et al. (2022). Use of machine learning to estimate the per-protocol effect of low-dose aspirin on pregnancy outcomes. *JAMA Network Open*, 5(3), e2143414.